Biologic Analytical Method Development

Reliable, rapid bioanalytical data to characterize your product.

Reach milestones faster.

Leveraging rapid bioanalytical data is critical to meeting milestones faster in drug development. Your product development program will be accelerated by using our extensive in-house analytical capabilities, technologies, and knowledge to deliver methods tailored to your molecule of interest.

Contact Us

From antibody discovery to preclinical and clinical studies, understanding drug exposure, safety, and metabolism are essential in accelerating your programs path to clinic and commercialization.

Abzena develop, execute and document phase appropriate analytical methods necessary to produce high-quality, well-characterized material and the data to support successful IND and marketing applications as you move towards commercialization.

Applying our expertise and experience, we develop rapid data packages that support your regulatory approvals with all global agencies.

Our Approach

Our approach focuses on developing and qualifying phase appropriate assays for a spectrum of safety, potency, purity, identity, and extended characterization that enable end-to-end support for:

  • Design and developability
  • Cell line development
  • Formulation development
  • Upstream and downstream process development
  • GMP manufacturing
  • Release and stability testing for GMP material

Our global team of expert analytical scientists develop analytical test methods and analytical qualification protocols, leveraging state-of-the-art instrumentation and a molecule-specific, customized approach to method development, qualification, and testing.

Methods can be developed de novo or transferred in from external laboratories.

LabZient, our Analytical Platform that Expedites the Path to IND

Increase Your Biopharmaceuticals Chances of Clinical Success with LabZient™

Analytical methods stand at the heart of successful drug development, playing a crucial role in ensuring the safety, efficacy, and quality of pharmaceutical products. In the ever-evolving landscape of drug development, analytical strategies provide the backbone for understanding and characterizing complex biologics and bioconjugates. Analytical methods and data are leveraged at each step of the development process and are used to inform regulatory decisions and confirm the delivery of safe and effective treatments to patients.

Discover how Abzena’s LabZient™ Analytical Platform revolutionizes the assessment of large molecules, such as antibodies and related drugs, enhancing operational efficiencies and improving a molecule’s chances at progressing through the development pathway.

By understanding your molecules’ attributes, we support future development activities with customized characterization assays.

Once methods are established, we optimize and refine them for the molecule of interest as part of an integrated service that supports cell line, process, and formulation development, and/or bioconjugation.

We provide transparent and regular communications to ensure we meet your program goals and timelines. Our capabilities include:

Viral clearance studies

  • Viral clearance studies


  • Protein A, L, G, CH1, affinity and custom solutions​
  • Biolayer Interferometry​


  • CESDS (reduced and non-reduced)​
  • SDSPAGE (reduced and non-reduced)​
  • Western Blot​
  • SE-(u)HPLC​
  • UV/Vis Spectroscopy​
  • rProtA​
  • Residual HCP​​


  • Antigen binding ELISA​
  • Biolayer Interferometry​
  • UV-Vis spectrophotometry


  • Appearance (USP790/EP2.9.2), (USP631/EP2.2.2), (USP855/EP2.2.1)​
  • Osmolality (USP785/EP2.2.85)​
  • pH (USP791/EP2.2.3)​
  • Extractable Volume​

Extended Characterization Analyses​

  • Intact Mass
    • Native intact mass​
    • Intact N-deglycosylated
  • Reduced Subunit Mass​
    • Native reduced intact mass
    • Reduced Subunit N-deglycosylated
  • Peptide Mapping
    • Amino acid composition​
    • Oxidation, Lysine Clipping​
    • Acetylation, Sulfation, Phosphorylation​
    • Deamidation, Pyroglutamate formation
    • Glycation​
    • Disulfide bond mapping​
    • Free sulfhydryl determination​
  • Glycopeptides​
    • N- and O- Linked glycan site mapping​
    • Glycan site occupancy​
  • Released N- and O-linked glycan identity and structure​
  • Quantification of Fucosylation​
  • Monosaccharide analysis​
  • Sialic acid content​
  • Glycan linkage analyses


  • Residual Ligand ELISA (Kit Based)​
  • Endotoxin (LAL), (USP85 / EP2.6.14)​
  • Sterility
  • Bioburden
  • TEM
  • Mycoplasma
  • Mycoplasmastasis

Cell-Based Assay Development

  • Fcg and neonatal Fc Receptors​
  • Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)​
  • Complement Dependent Cytotoxicity (CDC)​
  • C1q Binding
  • Antibody-Dependent Cellular Phagocytosis (ADCP)​
  • Custom Cell-Based Assays
  • Viability, Cytotoxicity, Apoptosis​

Small Molecule Characterization​

  • 1D and 2D NMR​
  • Mass Spectrometry

Antibody-Drug Conjugate Characterization​



  • Mass Spectrometry​
  • Liquid Chromatography​
  • Capillary Electrophoresis
  • ELISA and Bioassay​
  • NMR Spectroscopy


Let’s move medicine forward.

The asset you’re developing right now can make a real difference for human health. Let us leverage our expansive in-house capabilities, technologies, and molecule-specific methods to create a customized approach to speed that process.